MSD makes obesity play in up to $2bn deal for Hansoh’s GLP-1RA asset

MSD has entered an exclusive global licence agreement with Hansoh Pharma for a preclinical oral small molecule GLP-1RA.

Dec 21, 2024 - 06:00

MSD makes obesity play in up to $2bn deal for Hansoh’s GLP-1RA asset

MSD has entered an exclusive global licence agreement with Hansoh Pharma for a preclinical oral small molecule GLP-1RA.

Read the original article

Tags:

Previous Article

FDA approves Mesoblast’s Ryoncil for SR-aGvHD treatment

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

UnitedHealth’s next physician acquisition & the January health insurance churn

UnitedHealth’s next physician acquisition & the January...

Jan 8, 2024

Santhera and Catalyst to market DMD drug vamorolone in North America

Santhera and Catalyst to market DMD drug vamorolone in ...

Jul 19, 2023

South Korean pricing reform suggests more flexible drug reimbursement negotiations

South Korean pricing reform suggests more flexible drug...

Oct 30, 2024